Autoantibodies in systemic sclerosis and fibrosing syndromes: Clinical indications and relevance

Current Opinion in Rheumatology

Volumn 16, Issue 6, 2004, Pages 723-732

  Cepeda, Eduardo J ^a   Reveille, John D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Autoantibodies; Fibrosing disorders; Overlap syndrome; Raynaud phenomenon; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; CELL NUCLEUS ANTIGEN; CENTROMERE ANTIBODY; PHOSPHOLIPID ANTIBODY; RNA POLYMERASE; RO ANTIBODY;

ANTIBODY BLOOD LEVEL; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; EOSINOPHILIA MYALGIA SYNDROME; FIBROSIS; GRAFT VERSUS HOST REACTION; HUMAN; LUNG FIBROSIS; MORTALITY; PATHOGENESIS; POLYMYOSITIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FAMILY; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; SCLERODERMA; SKIN DISEASE; SYSTEMIC SCLEROSIS;

AUTOANTIBODIES; FIBROSIS; HUMANS; PROGNOSIS; SCLERODERMA, SYSTEMIC;

EID: 7044253658     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000144760.37777.fa     Document Type: Review

References (125)

1. Feghali-Bostwick C, Medsger TA Jr, Wright TM: Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003, 48:1956-1963. This study examined concordance for SSc in monozygotic and dizygotic twins. Concordance for SSc was found to be similar in monozygotic and dizygotic twins, and overall concordance for SSc was low in the twins (4.7%). SSc-associated serum autoantibodies occurred exclusively in patients with SSc. The study showed that inheritance may play a role in the development of serum autoantibodies in the "healthy" twin sibling of a patient with SSc.
2. Mayes MD, Reveille JD: Epidemiology, demographics, and genetics of systemic sclerosis. In: Systemic sclerosis. Edited by Clements PJ, Furst DE. Philadelphia: Lippincott Williams & Wilkins; 2003.
3. Reimer G, Steen VD, Penning CA, et al.: Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1988, 31:525-532.
4. Oddis CV, Okano Y, Rudert WA, et al.: Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum 1992, 35:1211-1217.
5. Blaszcyk M, Jarzabek-Chlorzelska M, Jablonska S, et al.: Autoantibodies to nucleolar antigens in systemic scleroderma: clinical correlations. Br J Dermatol 1990, 123:421-430.
6. Reddy R, Tan EM, Henning D, et al.: Detection of a nucleolar 7-2 ribonucleo-protein and a cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma. J Biol Chem 1983, 258:1383-1386.
7. Reimer G, Rose KM, Scheer U, et al.: Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest 1987, 79:65-72.
8. Kuwana M, Kaburaki J, Mimori T, et al.: Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 1993, 91:1399-1404.
9. Okano Y, Steen VD, Medsger TA Jr, et al.: Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993, 119:1005-1013.
10. Reveille JD, Solomon DH, American College of Rheumatology, ad hoc Committee on Immunologic Testing Guidelines.: Evidence-based guidelines for the use of immunologie tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003, 49:399-412. This committee report analyzes the published literature on the clinical usefulness of SSc autoantibodies, the different technologies in ordering these autoantibodies, and the application of these autoantibodies in prognosis, specifically in predicting the extent of cutaneous and pulmonary involvement.
11. McNeilage LJ, Youngchaiyud U, Whittingham S, et al.: Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 1989, 32:54-60.
12. Reveille JD, Fischbach M, McNearney T, et al.: Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001, 30:332-346.
13. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al.: Provalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003, 48:2246-2255. The authors established baseline estimates of the prevalence, incidence, survival, and disease characteristics based on 706 verified cases of SSc consisting primarily of black and white adults.
14. Wollersheim H, Thien T, Hoet MH, et al.: The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. Eur J Clin Invest 1989, 19:535-541.
15. Kallenberg CG, Wouda AA, Hoet MH, et al.: Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988, 47:634-641.
16. Weiner ES, Earnshaw WC, Senecal JL, et al.: Clinical associations of anticentromere antibodies and antibodies to topoisomurase I: a study of 355 patients. Arthritis Rheum 1988, 31:378-385.
17. Cutolo M, Pizzorni C, Tuccio M, et al.: Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) 2004, 43:719-726.
18. Steen VD, Powell DL, Medsger TA Jr, et al.: Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988, 31:196-203.
19. Ferri C, Valentini G, Cozzi F, et al.: Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002, 81:139-153.
20. Hesselstrand R, Scheja A, Shen GQ, et al.: The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003, 42:534-540.
21. Mitri GM, Lucas M, Fertig N, et al.: A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003, 48:203-209.
22. Allcock RJ, Forrest I, Corris PA, et al.: A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 2004, 43:596-602. This study estimated the prevalence and demographics of SSc, limited cutaneous SSc, diffuse cutaneous SSc, and anticentromere and anti-Scl-70 antibodies in northeast England.
23. Wigley FM, Wise RA, Miller R, et al.: Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 1992, 35:688-693.
24. Sulli A, Ghio M, Bezante GP, et al.: Blunted coronary flow reserve in systemic sclerosis. Rheumatology (Oxford) 2004, 43:505-509. The authors of this study investigated whether the noninvasive determination of coronary flow reserve, as evaluated by transthoracic Doppler echocardiography, might be a potential method to detect early dysfunction of cerdiovascular system in 44 patients with SSc without clinical signs or symptoms of cardiac impairment. Coronary flow reserve was found to be lower in SSc patients, which may point to an indirect sign of heart involvement in SSc.
25. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al.: Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002, 81:154-167.
26. Duncan SC, Winkelmann RK: Cancer and scleroderma. Arch Dermatol 1979, 115:950-955.
27. Peters-Golden M, Wise RA, Hochberg M, et al.: Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985, 12:1136-1139.
28. Roumm AD, Medsger TA: Cancer and systemic sclerosis: an epidemiologic study. Arthritis Rheum 1985, 28:1336-1340.
29. Abu Shakra M, Guillemin F, Lee P, et al.: Cancer in systemic sclerosis. Arthritis Rheum 1993, 36:460-464.
30. Rosenthal AK, McLaughlin JK, Gridley G, et al.: Incidence of cancer among patients with systemic sclerosis. Cancer 1995, 76:910-914.
31. Higuchi M, Horiuchi T, Ishibashi N, et al.: Anticentromore antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 2000, 19:123-126.
32. Kyndt X, Hebbar M, Queyrel V, et al.: Systemic scleroderma and cancer: search for predictive factors of cancer in 123 patients with scleroderma [in French]. Rev Med Interne 1997, 18:528-532.
33. Derk CT, Sakkas LI, Rasheed M, et al.: Autoantibodies in patients with systemic sclerosis and cancer: a case-control study. J Rheumatol 2003, 30:1994-1996. In this case-control study, the authors found no statistically significant difference in the frequency of ACA and anti-Scl-70 antibodies among patients with SSc with and without the diagnosis of cancer. This study conflicts with previous studies that certain autoantibodies may represent risk factors for the development of cancer in patients with SSc
34. Weiner ES, Hildebrandt S, Senecal JL, et al.: Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease: a prospective study. Arthritis Rheum 1991, 34:68-77.
35. Tramposch HD, Smith CD, Senecal JL, et al.: A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum 1984, 27:121-124.
36. Vasquez-Abad D, Russell CA, Cusick SM, et al.: Longitudinal study of anticentromere and antitopoisomerase-I isotypes. Clin Immunol Immunopathol 1995, 74:257-270.
37. Sato H, Lagan AL, Alexopoulou C, et al.: The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum 2004, 50:558-564. In this study of 214 SSc patients from the United Kingdom, the authors investigated TNF polymorphisms in scleroderma. Anti-Scl-70 showed a positive association with the TNF-857Tallele and a negative association with both TNF-1031C and TNF-863A alleles.
38. Gussin HA, Ignat P, Varga J, et al.: Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44:376-383.
39. Greidinger EL, Flaherty KT, White B, et al.: African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998, 114:801-807.
40. Nishijima C, Sato S, Hasegawa M, et al.: Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatol 2001, 40:406-409.
41. Murata I, Takenaka K, Shinohara S, et al.: Diversity of myocardial involvement in systemic sclerosis: an 8-year study of 95 Japanese patients. Am Heart J 1998, 135:960-969.
42. Jacobsen S, Ullman S, Shen GQ, et al.: Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001, 28:2454-2459.
43. Rothfield N, Kurtzman S, Vasques-Abad D, et al.: Association of antitopoisomerase I with cancer. Arthritis Rheum 1992, 35:724.
44. Hu PQ, Fertig N, Medsger TA Jr, et al.: Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003, 48:1363-1373. This article revisits the utility of the anti-Scl-70 ELISA in the care of patients with SSc. Contrary to some previous studies, the authors found that serum levels of anti-Scl-70 antibody (measured by ELISA) correlate positively with disease severity and disease activity in SSc.
45. Gilchrist FC, Bunn C, Foley PJ, et al.: Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun 2001, 2:76-81.
46. Brouwer R, Hengstman GJ, Vree Egberts W, et al.: Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001, 60:116-123.
47. Marguerie C, Bunn CC, Copier J, et al.: The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992, 71:327-336.
48. Raijmakers R, Vree Egberts W, van Venrooij WJ, et al.: Protein-protein interactions between human exosome components support the assembly of Rnase PH-type subunits into a six-membered PNPase like ring. J Mol Biol 2002, 323:653-663.
49. Alderuccio F, Chan EK, Tan EM, et al.: Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex. J Exp Med 1991, 173:941-952.
50. Raijmakers R, Renz M, Wiemann C, et al.: PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. Arthritis Rheum 2004, 50:565-569. When combining the long PM-Scl-75 isoform in addition to the PM-Scl-100 in ELISA, the authors noted that there is an increase in the number of patients in whom anti-PM-Scl autoantibodies can be detected.
51. van Eenennaam H, Vogelzangs JHP, Lugtenberg D, et al.: Identity of the RNase MRP-and RNase P-associated Th/To autoantigen. Arthritis Rheum 2002, 46:3266-3272.
52. Harvey G, Black C, Maddison P, et al.: Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 1997, 24:477-484.
53. Kuwana M, Kimura K, Hirakata M, et al.: Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis 2002, 61:842-846.
54. Okano Y, Medsger TA Jr: Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990, 33:1822-1828.
55. Van Eenennaam H, Vogelzangs JH, Bisschops L, et al.: Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin Exp Immunol 2002, 130:532-540.
56. Falkner D, Wilson J, Medsger TA Jr, et al.: HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies. Arthritis Rheum 1998, 41:74-80.
57. Yamane K, Ihn H, Kubo M, et al.: Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma. Rheumatology (Oxford) 2001, 40:683-686.
58. Chang M, Wang R, Yangco D, et al.: Analysis of autoantibodies against RNA polymerases using immunoaffinity-purifed RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay. Clin Immunol Immunopathol 1998, 89:71-78.
59. Bunn CC, Denton CP, Shi-Wen X, et al.: Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998, 37:15-20.
60. Satoh M, Kuwana M, Ogasawara T, et al.: Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients. J Immunol 1994, 153:5838-5848.
61. Bardoni A, Ossi P, Salvini R, et al.: Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis. Clin Exp Rheumatol 2003, 21:301-306. In this study of Italian patients with SSc, the authors found anti-RNA-polymerase antibodies to be less frequent in Italian patients than in Caucasian patients from the United Kingdom or the United States. Also, anti-RNA-polymerase I and III antibodies were associated with diffuse cutaneous involvement and male gender.
62. Fanning GC, Welsh KI, Bunn C, et al.: HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol 1998, 37:201-207.
63. Falkner D, Wilson J, Fertig N, et al.: Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin). J Rheumatol 2000, 27:1196-1202.
64. Kuwana M, Pandey JP, Silver RM, et al.: HLA class II alleles in systemic sclerosis patients with anti-RNA polymerase I/III antibody: associations with subunit reactivities. J Rheumatol 2003, 30:2392-2397. Previous studies have failed to detect any statistically significant associations between the presence of anti-RNAP I/III antibodies and HLA-DRB1 or DOB1 alleles. The authors of this study found that the presence of anti-RNAP I/III antibodies was associated with HLA-DRB1*0405 and DQB1*0401 in Japanese SSc patients, and with HLA-DRB3*02 in Caucasians.
65. Baserga SJ, Yang XD, Steitz JA: An intact Box C sequence in the U3 snRNA is required for binding of fibrillarin, the protein common to the major family of nucleolar snRNPs. EMBO J 1991, 10:2645-2651.
66. Arnett FC, Reveille JD, Goldstein R, et al.: Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): an immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996, 39:1151-1156.
67. Tormey VJ, Bunn CC, Denton CP, et al.: Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 2001, 40:1157-1162.
68. Yamane K, Ihn H, Kubo M, et al.: Anti-U3 snRNP antibodies in localised scleroderma. Ann Rheum Dis 2001, 60:1157-1158.
69. Mimori T, Akizuki M, Yamagata H, et al.: Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest 1981, 63:611-620.
70. Isern RA, Yaneva M, Weiner E, et al.: Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. Am J Med 1992, 93:307-312.
71. Takeda Y, Dynan WS: Autoantibodies against DNA double-strand break repair proteins. Front Biosci 2001, 6:01412-01422.
72. Franceschini F, Cavazzana I, Generali D, et al.: Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. J Rheumatol 2002, 29:1393-1397.
73. Picillo U, Migliaresi S, Marcialis MR, et al.: Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis. Autoimmunity 1995, 20:1-7.
74. Black CM, Stevens WM: Pregnancy in patients with rheumatic diseases: scleroderma. Rheum Dis Clin North Am 1989, 15:193-212.
75. Antonioli CM, Danieli E, Airo P, et al.: More on anticardiolipin and anti-beta2 glycoprotein I in systemic sclerosis. Ann Rheum Dis 2003, 62:589-590.
76. Ihn H, Sato S, Fujimoto M, et al.: Measurement of anticardiolipin antibodies by ELISA using beta 2-glycoprotein I (beta 2-GPI) in systemic sclerosis. Clin Exp Immunol 1996, 105:475-479.
77. Malia RG, Greaves M, Rowlands LM, et al.: Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations. Clin Exp Immunol 1988, 73:456-460.
78. Passaleva A, Massai G, Matucci-Cerinic M, et al.: Immunological abnormalities in a group of patients with limited cutaneous systemic sclerosis and prominent vascular disease. Autoimmunity 1990, 6:283-291.
79. Katayama I, Otoyama K, Kondo S, et al.: Clinical manifestations in anticardiolipin antibody-positive patients with progressive systemic sclerosis. J Am Acad Dermatol 1990, 23:198-201.
80. Merkel PA, Chang Y, Pierangeli SS, et al.: The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996, 101:576-583.
81. Vayssairat M, Abuaf N, Baudot N, et al.: Abnormal IgG cardiolipin antibody titers in patients with Raynaud's phenomenon and/or related disorders: prevalence and clinical significance. J Am Acad Dermatol 1998, 38:555-558.
82. Naldi L, Locati F, Marchesi L, et al.: Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case-control study. Ann Rheum Dis 1993, 52:219-222.
83. Knapik-Kordecka M, Wysokinski WE: Clinical spectrum of Raynaud's phenomenon in patients referred to vascular clinic. Cardiovasc Surg 2000, 8:457-462.
84. Bongard O, Bounameaux H, Miescher PA, et al.: Association of anticardiolipin antibodies and abnormal nailfold capillaroscopy in patients with systemic lupus erythematosus. Lupus 1995, 4:142-144.
85. Caccavo D, Del Porto F, Garzia P, et al.: Raynaud's phenomenon and antiphospholipid antibodies in systemic lupus erythematosus: is there an association? Ann Rheum Dis 2003, 62:1003-1005.
86. Sato S, Fujimoto M, Hasegawa M, et al.: Antiphospholipid antibody in localised scleroderma. Ann Rheum Dis 2003, 62:771-774.
87. Kameda H, Kuwana M, Hama N, et al.: Coexistence of serum anti-DNA topoisomerase I and anti-Sm antibodies: report of 3 cases. J Rheumatol 1997, 24:400-403.
88. Sharp GC, Irvin WS, May CM: Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976, 295:1149-1154.
89. Ihn H, Yamane K, Yazawa N, et al.: Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol 1999, 117:383-387.
90. Lundberg I, Hedfors E: Clinical course of patients with anti-RNP antibodies: a prospective study of 32 patients. J Rheumatol 1991, 18:1511-1519.
91. Jablonska S, Blaszczyk M: Scleroderma overlap syndromes. Adv Exp Med Biol 1999, 455:85-92.
92. Frandsen PB, Kriegbaum NJ, Ullman S, et al.: Follow-up of 151 patients with high-titer U1RNP antibodies. Clin Rheumatol 1996, 15:254-260.
93. Rasmussen EK, Ullman S, Hoier-Madsen M: Clinical implications of ribonucleoprotein antibody. Arch Dermatol 1987, 123:601-605.
94. Kasukawa R: Mixed connective tissue disease. Intern Med 1999, 38:386-393.
95. Yamane K, Ihn H, Kubo M, et al.: Anti-U1RNP antibodies in patients with localized scleroderma. Arch Dermatol Res 2001, 293:455-459.
96. Bell S, Krieg T, Meurer M, et al.: Antibodies to Ro/SSA detected by ELISA: correlation with clinical features in systemic scleroderma. Br J Dermatol 1989, 121:35-41.
97. Andonopoulos AP, Drosos AA, Skopouli FN, et al.: Sjogren's syndrome in rheumatoid arthritis and progressive systemic sclerosis: a comparative study. Clin Exp Rheumatol 1989, 7:203-205.
98. Drosos AA, Andonopoulos AP, Costopoulos JS, et al.: Sjogren's syndrome in progressive systemic sclerosis. J Rheumatol 1988, 15:965-968.
99. Ruffati A, Sinico RA, Radice A, et al.: Auto antibodies to proteinase 3 and myeloperoxidase in systemic sclerosis. J Rheumatol 2002, 29:918-923.
100. Pignone A, Scaletti C, Matucci-Cerinic M: Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 1998, 16:527-532.
101. Negi VS, Tripathy NK, Misra R, et al.: Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998, 25:462-466.
102. Salogin KV, LeTonqueze M, Saraux A, et al.: Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 1997, 102:178-185.
103. Ihn H, Sato S, Fujimoto M, et al.: Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 2000, 119:203-209.
104. Wusirika R, Ferri C, Marin M, et al.: The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis: a study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol 2003, 120:596-606. There are limited data on antiendothelial cell antibodies in scleroderma. However, this study is consistent with other studies showing a possible relation with antiendothelial cell antibodies and pulmonary fibrosis.
105. Tan FK, Arnett FC, Antohi S, et al.: Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scloroderma and other connective tissue diseases. J Immunol 1999, 163:1066-1072.
106. Lundberg I, Antohi S, Takeuki K, et al.: Kinetics of anti-fibrillin-1 autoantibodies in MCTD and CREST syndrome. J Autoimmun 2000, 14:267-274.
107. Asano Y, Ihn H, Yamane K, et al.: The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis. J Invest Dermatol 2003, 120:204-210.
108. Grigolo B, Mazzetti I, Borzi RM, et al.: Mapping of topoisomerase II alpha epitopes recognized by autoantibodies in idiopathic pulmonary fibrosis. Clin Exp Immunol 1998, 114:339-346.
109. Meliconi R, Bestagno M, Sturani C, et al.: Autoantibodies to DNA topoisomerase II in cryptogenic fibrosing alveolitis and connective tissue disease. Clin Exp Immunol 1989, 76:184-189.
110. Grigolo B, Mazzetti I, Meliconi R, et al.: Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35. Clin Exp Immunol 2000, 121:539-543.
111. Chang YH, Hwang J, Shang HF, et al.: Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM. Diabetes 1996, 45:408-414.
112. Zuklys KL, Szer IS, Szer W, et al.: Autoantibodies to DNA topoisomerase II in juvenile rheumatoid arthritis. Clin Exp Immunol 1991, 84:245-249.
113. Hoffmann A, Heck MM, Bordwell BJ, et al.: Human autoantibody to topoisomerase II. Exp Cell Res 1989, 180:409-418.
114. Hayakawa I, Minoru H, Takehara K, et al.: Anti-DNA topoisomerase II alpha autoantibodies in localized scleroderma. Arthritis Rheum 2004, 50:227-232.
115. Nagai M, Hasegawa M, Takehara K, Sato S: Novel autoantibody to Cu/Zn superoxide dismutase in patients with localized scleroderma. J Invest Dermatol 2004, 122:594-601.
116. Bell SA, Faust H, Mittermuller J, et al.: Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association. Br J Derrnatol 1996, 134:848-854.
117. Chosidow O, Bagot M, Vernant JP, et al.: Sclerodeimatous chronic graft-versus-host disease: analysis of seven cases. J Am Acad Dermatol 1992, 26:49-55.
118. Quarantara S, Shulman H, Ahmed A, et al.: Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol 1999, 91:106-116.
119. Chan EY, Lawton JW, Lie AK, et al.: Autoantibody formation after allogeneic bone marrow transplantation: correlation with the reconstitution of CD5+ B cells and occurrence of graft-versus-host disease. Pathology 1997, 29:184-188.
120. Martin SJ, Audrain MA, Oksman F, et al.: Antineutrophil cytoplasmic antibodies (ANCA) in chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997, 20:45-48.
121. Kaufman LD, Varga J, Gomez-Reino JJ, et al.: Autoantibodies in sera from patients with L-tryptophan-associated eosinophilia-myalgia syndrome: demonstration of unique antigen-antibody specificities. Clin Immunol Immunopathol 1995, 76:115-119.
122. Carreira PE, Montalvo MG, Kaufman LD, et al.: Antiphospholipid antibodies in patients with eosinophilia myalgia and toxic oil syndrome. J Rheumatol 1997, 24:69-72.
123. Mackay-Wiggan JM, Cohen DJ, Hardy MA, et al.: Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 2003, 48:55-60.
124. Valeri A, Joseph R, Radhakrishnan J, et al.: A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis parents. Clin Nephrol 1999, 51:116-121.
125. Gambichler T, Paech V, Kreuter A, et al.: Nephrogenic fibrosing dermopathy. Clin Exp Dermatol 2004, 29:258-260.